Krebs board approves merger with Ipca Labs at 7:200 share swap

Nclt Scheme FiledStrategic Transactions View source PDF

KREBSBIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-8.2%1-day move

₹66.24

prior close

₹65.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-5.8—-3.3—-8.2-9.4-11.4-12.1-11.7-18.5-18.5———

Up moveDown movePending

AI summary

Krebs Biochemicals board approved a scheme of amalgamation with Ipca Laboratories under Sections 230-232. Shareholders will get 7 Ipca shares (Re. 1 face value) for every 200 Krebs shares (Rs. 10 face value). No cash consideration. Krebs had FY26 income of Rs. 26 Cr, mostly from Ipca conversion charges. Ipca had FY26 income of Rs. 7,431 Cr. It is a related party deal at arms length. Appointed date: April 1, 2026.

Likely market impact

Krebs holders to get 7 Ipca shares per 200 held. Merger awaits NCLT, SEBI, and shareholder approvals.